Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy

Findings published in Neurology show improvements in upper-limb motor function, activities of daily living, and quality of life were sustained for at least two years

July 14, 2026 16:18 ET | Source: Mobia Medical, Inc.

Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the publication of two-year follow-up data from the VNS-REHAB study in Neurology, the official peer-reviewed journal of the American Academy of Neurology.

The findings demonstrate that statistically significant and clinically meaningful improvements in upper-limb motor impairment and function, ability to perform activities of daily living, and quality of life were sustained for at least two years following completion of in-clinic Vivistim Paired VNS Therapy.

With its publication, this data now represents some of the most comprehensive longitudinal evidence to date for any intervention approved for chronic ischemic stroke recovery.

The two-year follow-up data, published in Neurology, reports outcomes from 49 participants in the VNS-REHAB pivotal trial, demonstrating a high responder rate and substantial improvements in impairment and function including:

Clinically meaningful response on the Fugl-Meyer Assessment of Upper Extremity impairment (FMA-UE) and/or the Wolf Motor Function Test (WMFT) in 76% of participants Average improvement of +7.5 points from baseline on the FMA-UE, exceeding the minimum clinically important difference (MCID) of ≥6 points Average improvement of +0.63 from baseline on the WMFT, exceeding the MCID of ≥0.4 points Importantly, the...